899431-48-2Relevant academic research and scientific papers
THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS
-
Page/Page column 70, (2008/06/13)
The present invention relates to the use of selective P2X7 receptor antagonists of formula (I), or a pharmaceutically acceptable salt or prodrug thereof wherein D, R1 and R2 are as defined in claim 1, for the treatment of neuropathic pain, chronic inflammatory pain, inflammation, neurodegeneration and for promoting neuroregeneration.
Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists
Nelson, Derek W.,Gregg, Robert J.,Kort, Michael E.,Perez-Medrano, Arturo,Voight, Eric A.,Wang, Ying,Grayson, George,Namovic, Marian T.,Donnelly-Roberts, Diana L.,Niforatos, Wende,Honore, Prisca,Jarvis, Michael F.,Faltynek, Connie R.,Carroll, William A.
, p. 3659 - 3666 (2007/10/03)
1-Benzyl-5-aryltetrazoles were discovered to be novel antagonists for the P2X? receptor. Structure-activity relationship (SAR) studies were conducted around both the benzyl and phenyl moieties. In addition, the importance of the regiochemical substitution
